TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06618287: A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors

Sponsor: Bristol-Myers Squibb · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 416 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$8,089,620

Rescue Site Savings

+$5,340,720

Unlock Full NCT06618287 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06618287 Rescue Dossier →